Sergio Goicochea-Lugo

Sergio Goicochea-Lugo

Auto-generated profile, based on publicly available information

Sergio Goicochea-Lugo

Affiliations Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru, EviSalud—Evidencias en Salud, Lima, Peru

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2019 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
JZJessica Hanae Zafra-Tanaka
Jessica Hanae Zafra-Tanaka
SGSergio Goicochea-Lugo
Sergio Goicochea-Lugo
David Villarreal-ZegarraDavid Villarreal-Zegarra
David Villarreal-Zegarra
ATAlvaro Taype-Rondan
Alvaro Taype-Rondan
Clinical Practice Guidelines (CPGs) should follow an adequate methodology using an evidence-based approach in order to provide reliable recommendations. However, little is known regarding the quality of CPGs for Depression, which precludes its adequate use by stakeholders and mental health professionals. Thus, the aim of this study was to conduct a scoping review to describe the characteristics and quality of CPGs for Depression in adults. We searched CPGs for Depression in adults in eighteen databases. We included those that were published in English or Spanish between January 2014 and May 2018 and were based on systematic reviews of the evidence. Two independent authors extracted the characteristics, type and number of recommendations, and quality (using the Appraisal of Guidelines for Research and Evaluation-II [AGREE-II]) of each included CPG. We included eleven CPGs, of which 9/11 did not include the participation of patients in the development of the CPG, 4/11 CPGs had a score ≥ 70% in the overall evaluation of AGREE-II, and 3/11 CPGs had a score ≥ 70% in its third domain (rigor of development). In addition, only 5/11 CPGs shared their search strategy, while only 4/11 listed the selected studies they used to reach recommendations, and 7/11 CPGs did not clearly state which methodology they used to translate evidence into a recommendation. Most of evaluated CPGs did not take into account the patient’s viewpoints, achieved a low score in the rigor of development domain, and did not clearly state the process used to reach the recommendations. Stakeholders, CPCGs developers, and CPGs users should take this into account when choosing CPGs, and interpreting and putting into practice their issued recommendations.

27 September 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
KFKevin Flores-Lovon
Kevin Flores-Lovon
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
SMSebastian A Medina-Ramirez
Sebastian A Medina-Ramirez
DFDaniel Fernandez-Guzman
Daniel Fernandez-Guzman
BCBrenda Caira-Chuquineyra
Brenda Caira-Chuquineyra
SGSergio Goicochea-Lugo
Sergio Goicochea-Lugo
Objectives To evaluate the efficacy of antituberculosis therapy on pregnancy outcomes in infertile women with genital tuberculosis. Design Systematic review. Data sources We searched in PubMed/MEDLINE, CENTRAL and EMBASE up to 15 January 2023. Additionally, we manually search the reference lists of included studies. Eligibility criteria We included randomised controlled trials (RCT), non-RCTs (non-RCT) and cohort studies that evaluated the effects of antituberculosis treatment on pregnancy outcomes in infertile women with genital tuberculosis compared with not receiving antituberculosis treatment or receiving the treatment for a shorter period. Data extraction and synthesis Two independent reviewers extracted data. We used Cochrane Risk of Bias 1.0 and Risk Of Bias In Non-randomised Studies tools for risk of bias assessment and meta-analysis was not performed. We used Grading of Recommendations, Assessment, Development and Evaluations approach to assess the certainty of the evidence. Results Two RCTs and one non-RCT were included. The antituberculosis regimens were based on isoniazid, rifampicin, pyrazinamide and ethambutol for 6–12 months. In women without structural damage, very low certainty of evidence from one RCT showed that the antituberculosis treatment may have little to no effect on pregnancy, full-term pregnancy, abortion or intrauterine death and ectopic pregnancy, but the evidence is very uncertain. In women with structural damage, very low certainty of evidence from one non-RCT showed that the antituberculosis treatment may reduce the pregnancy rate (297 fewer per 1000, 95% CI −416 to −101), but the evidence is very uncertain. In addition, very low certainty of evidence from one RCT compared a 9-month vs 6-month antituberculosis treatment regimen showed similar effects between the schemes, but the evidence is very uncertain. Two RCTs reported that no adverse events of antituberculosis treatment were noted or were similar in both groups. Conclusion The effect of antituberculosis treatment on pregnancy outcomes in infertile women with genital tuberculosis is very uncertain. PROSPERO registration number CRD42022273145.

1 March 2020 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
JFJose Ernesto Fernandez-Chinguel
Jose Ernesto Fernandez-Chinguel
SGSergio Goicochea-Lugo
Sergio Goicochea-Lugo
David Villarreal-ZegarraDavid Villarreal-Zegarra
David Villarreal-Zegarra
ATAlvaro Taype-Rondan
Alvaro Taype-Rondan
JZJessica Hanae Zafra-Tanaka
Jessica Hanae Zafra-Tanaka

6 December 2020 in ACTA MEDICA PERUANA
Verified
Journal Article
Open access
PDF file
JBJessica Bravo-Zúñiga
Jessica Bravo-Zúñiga
JHJuana Hinostoza-Sayas
Juana Hinostoza-Sayas
SLSergio Goicochea- Lugo
Sergio Goicochea- Lugo
GDGandy Dolores-Maldonado
Gandy Dolores-Maldonado
ACAna Brañez Condorena
Ana Brañez Condorena
HGHéctor Garavito-Farro
Héctor Garavito-Farro
El presente artículo resume la guía de práctica clínica (GPC) para tamizaje, diagnóstico y manejo de los pacientes con enfermedad renal crónica (ERC) en los estadios 1 al 3 en el Seguro Social del Perú (EsSalud). Para el desarrollo de esta GPC, se conformó un grupo elaborador de la guía (GEG) que incluyó especialistas clínicos y metodólogos, el cual formuló ocho preguntas clínicas. Para responder cada pregunta se realizaron búsquedas sistemáticas de revisiones sistemáticas y, cuando fue considerado pertinente, de estudios primarios; y se seleccionó la evidencia pertinente. La certeza de la evidencia fue evaluada usando la metodología Grading of Recommendations Assessment, Development, and Evaluation (GRADE). En reuniones periódicas, el GEG usó la metodología GRADE para revisar la evidencia y emitir las recomendaciones. Se emitieron ocho recomendaciones (cuatro fuertes y cuatro condicionales), 29 puntos de buena práctica clínica, y tres flujogramas.

1 May 2021 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
ABAna Brañez-Condorena
Ana Brañez-Condorena
SGSergio Goicochea-Lugo
Sergio Goicochea-Lugo
JZJessica Hanae Zafra-Tanaka
Jessica Hanae Zafra-Tanaka
NBNaysha Becerra-Chauca
Naysha Becerra-Chauca
VFVirgilio E. Failoc-Rojas
Virgilio E. Failoc-Rojas
ATAlvaro Taype-Rondan
Alvaro Taype-Rondan
BACKGROUND: The most-used equations for estimating the glomerular filtration rate (GFR) are the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) equations. However, it is unclear which of these shows better performance in Latin America. OBJECTIVE: To assess the performance of two equations for estimated GFR (eGFR) in Latin American countries. DESIGN AND SETTING: Systematic review and meta-analysis in Latin American countries. METHODS: We searched in three databases to identify studies that reported eGFR using both equations and compared them with measured GFR (mGFR) using exogenous filtration markers, among adults in Latin American countries. We performed meta-analyses on P30, bias (using mean difference [MD] and 95% confidence intervals [95% CI]), sensitivity and specificity; and evaluated the certainty of evidence using the GRADE methodology. RESULTS: We included 12 papers, and meta-analyzed six (five from Brazil and one from Mexico). Meta-analyses that compared CKD-EP I using creatinine measured with calibration traceable to isotope dilution mass spectrometry (CKD-EP I-Cr IDMS) and using MDRD-4 IDMS did not show differences in bias (MD: 055 ml/min/1.73m(2) ; 95% CI: -334 to 4.43), P30 (MD: 4%; 95% CI: -2% to 11%), sensitivity (76% and 75%) and specificity (91% and 89%), with very low certainty of evidence for bias and P30, and low certainty of evidence for sensitivity and specificity. CONCLUSION: We found that the performances of CKD-EPI-Cr IDMS and MDRD-4 IDMS did not differ significantly. However, since most of the meta-analyzed studies were from Brazil, the results cannot be extrapolated to other Latin American countries.

12 April 2023 in Revista de Gastroenterología del Perú
Verified
Journal Article
Open access
PDF file
EGEdson Guzmán-Calderón
Edson Guzmán-Calderón
WAWilen Horacio Suárez Ale
Wilen Horacio Suárez Ale
LCLesly Chávez-Rimache
Lesly Chávez-Rimache
LJLuygy Zavaleta Jara
Luygy Zavaleta Jara
MGMiguel José Díaz Gonzales
Miguel José Díaz Gonzales
VSVladimir Santos Sánchez
Vladimir Santos Sánchez
El presente artículo resume la guía de práctica clínica (GPC) para el manejo de la pancreatitis aguda en el Seguro Social del Perú (EsSalud). Su objetivo es proveer recomendaciones clínicas basadas en evidencia para el manejo de la pancreatitis aguda en EsSalud. Se conformó un grupo elaborador de la guía (GEG) que incluyó médicos especialistas y metodólogos. El GEG formuló 7 preguntas clínicas a ser respondidas por la presente GPC. Se realizó búsquedas sistemáticas de revisiones sistemáticas y –cuando fue considerado pertinente– estudios primarios en PubMed durante el 2022. Se seleccionó la evidencia para responder cada una de las preguntas clínicas planteadas. La certeza de la evidencia fue evaluada usando la metodología Grading of Recommendations Assessment, Development, and Evaluation (GRADE). En reuniones de trabajo periódicas, el GEG usó la metodología GRADE para revisar la evidencia y formular las recomendaciones, los puntos de buenas prácticas clínicas y flujogramas correspondientes. Finalmente, la GPC fue aprobada con Resolución N° 105-IETSI-ESSALUD-2022. La presente GPC abordó 7 preguntas clínicas sobre fluidoterapia, momento de inicio de nutrición enteral, analgesia, tipo de nutrición, tratamiento antibiótico y quirúrgico. En base a dichas preguntas se formularon 8 recomendaciones (1 fuerte y 7 condicionales), 13 BPC, y 1 flujograma. El pres as en evidencia de la GPC para el manejo de la pancreatitis aguda en EsSalud.